• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality.托珠单抗联合地塞米松的成本效益治疗可降低 COVID-19 死亡率。
Clin Infect Dis. 2021 Dec 6;73(11):2116-2118. doi: 10.1093/cid/ciab409.
2
Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19.严重 COVID-19 的调整剂量地塞米松和托珠单抗联合治疗。
Yonsei Med J. 2022 May;63(5):430-439. doi: 10.3349/ymj.2022.63.5.430.
3
Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019.加速严重急性呼吸综合征冠状病毒 2 的进化：将地塞米松和托珠单抗联合用于严重 2019 冠状病毒病的风险。
J Infect Dis. 2021 Sep 17;224(6):934-937. doi: 10.1093/infdis/jiab328.
4
Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.比较托珠单抗与皮质类固醇治疗 COVID-19 患者的疗效：系统评价和荟萃分析。
Daru. 2022 Jun;30(1):211-228. doi: 10.1007/s40199-021-00430-8. Epub 2022 Jan 27.
5
Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.中重度 COVID-19 呼吸道疾病的治疗：成本效用分析。
Sci Rep. 2021 Sep 7;11(1):17787. doi: 10.1038/s41598-021-97259-7.
6
Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See.托珠单抗治疗重症2019冠状病毒病的成本效益：看或不看
Clin Infect Dis. 2021 Dec 6;73(11):2119-2120. doi: 10.1093/cid/ciab459.
7
Efficacy of tocilizumab in COVID-19: A review of the current evidence.托珠单抗治疗 COVID-19 的疗效：当前证据综述。
Sci Prog. 2021 Jul-Sep;104(3):368504211030372. doi: 10.1177/00368504211030372.
8
Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019.翻转的炎症时间与抗严重急性呼吸综合征冠状病毒 2 抗体的作用：优化托珠单抗治疗 2019 年冠状病毒病。
J Infect Dis. 2022 Aug 12;226(1):1-5. doi: 10.1093/infdis/jiac090.
9
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
10
Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.托珠单抗治疗 COVID-19 住院患者：一项随机对照试验的荟萃分析。
Lung. 2021 Jun;199(3):239-248. doi: 10.1007/s00408-021-00451-9. Epub 2021 May 29.

引用本文的文献

1
An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19.评估vilobelimab（抗C5a）作为治疗重症新型冠状病毒肺炎机械通气患者的一种具有成本效益的选择。
Am J Health Syst Pharm. 2025 Apr 29;82(9):e438-e446. doi: 10.1093/ajhp/zxae318.
2
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review.基于模型的 COVID-19 药物治疗在大流行情况下的经济评估的经验教训：系统评价的结果。
Pharmacoeconomics. 2024 Jun;42(6):633-647. doi: 10.1007/s40273-024-01375-x. Epub 2024 May 10.
3
Effect of plant produced Anti-hIL-6 receptor antibody blockade on pSTAT3 expression in human peripheral blood mononuclear cells.植物源性抗人 IL-6 受体抗体阻断对人外周血单个核细胞中 pSTAT3 表达的影响。
Sci Rep. 2023 Jul 24;13(1):11927. doi: 10.1038/s41598-023-39106-5.
4
[Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients.托珠单抗治疗 COVID-19 患者的疗效和边际成本。
Farm Hosp. 2023 Jan-Feb;47(1):T10-T15. doi: 10.1016/j.farma.2022.12.014. Epub 2022 Dec 28.
5
RETRACTED: Environmental Risk Assessment of Dexamethasone Sodium Phosphate and Tocilizumab Mixture in Zebrafish Early Life Stage ().撤回：地塞米松磷酸钠与托珠单抗混合物对斑马鱼幼鱼期的环境风险评估（）
Toxics. 2022 May 25;10(6):279. doi: 10.3390/toxics10060279.
6
Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.预防和控制 COVID-19 的干预措施的成本效益：85 项建模研究的系统评价。
J Glob Health. 2022 Jun 15;12:05022. doi: 10.7189/jogh.12.05022.
7
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.针对 SARS-CoV-2 的被动免疫疗法：从基于血浆的疗法到单一强效抗体，以在与变异体的竞赛中保持领先地位。
BioDrugs. 2022 May;36(3):231-323. doi: 10.1007/s40259-022-00529-7. Epub 2022 Apr 27.
8
Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study.与基于体重给药相比，在新冠肺炎危重症患者中降低托珠单抗固定剂量至400mg静脉注射：一项前后队列研究。
Lancet Reg Health Am. 2022 Jul;11:100228. doi: 10.1016/j.lana.2022.100228. Epub 2022 Mar 23.
9
Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations.COVID-19 的诊断与治疗：经济评估的实时系统综述。
Value Health. 2022 May;25(5):773-784. doi: 10.1016/j.jval.2022.01.001. Epub 2022 Feb 16.
10
Tocilizumab cost effective in reducing COVID-19-related deaths.托珠单抗在降低新冠肺炎相关死亡方面具有成本效益。
PharmacoEcon Outcomes News. 2021;879(1):28. doi: 10.1007/s40274-021-7751-7. Epub 2021 May 29.

本文引用的文献

1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
2
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
3
Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.新冠病毒肺炎中白细胞介素-6受体抑制——冷却炎症“汤液”
N Engl J Med. 2021 Apr 22;384(16):1564-1565. doi: 10.1056/NEJMe2103108. Epub 2021 Feb 25.
4
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
5
Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis.COVID-19 感染后患者的呼吸功能：系统评价和荟萃分析。
Pulmonology. 2021 Jul-Aug;27(4):328-337. doi: 10.1016/j.pulmoe.2020.10.013. Epub 2020 Nov 25.
6
Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge.早期给予白细胞介素 6 抑制剂治疗重症 COVID-19 患者与降低插管率、降低死亡率和增加出院率相关。
Int J Infect Dis. 2020 Oct;99:28-33. doi: 10.1016/j.ijid.2020.07.023. Epub 2020 Jul 25.
7
Clinical Characteristics of Covid-19 in New York City.纽约市新冠肺炎的临床特征
N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi: 10.1056/NEJMc2010419. Epub 2020 Apr 17.
8
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.《健康与医疗领域成本效益分析的实施、方法学实践和报告推荐：第二版》。
JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.

托珠单抗联合地塞米松的成本效益治疗可降低 COVID-19 死亡率。

Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality.

机构信息

Section of Infectious Diseases, Department of Internal Medicine, School of Medicine, Boston University, Boston, Massachusetts, USA.

出版信息

Clin Infect Dis. 2021 Dec 6;73(11):2116-2118. doi: 10.1093/cid/ciab409.

DOI:10.1093/cid/ciab409
PMID:33956936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8135952/
Abstract

Recent randomized trials suggest that interleukin-6 inhibitors reduce mortality due to severe coronavirus disease 2019. Using a decision tree model, we found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16 520 per quality-adjusted life year gained (95% credible interval, 10 760-51 530).

摘要

最近的随机临床试验表明，白细胞介素-6 抑制剂可降低因严重 2019 年冠状病毒病导致的死亡率。我们使用决策树模型发现，托珠单抗具有成本效益，估计每获得一个质量调整生命年的增量成本效益比为 16520 美元（95%可信区间为 10760-51530）。